Agilent Technologies Inc. has declared a quarterly dividend of 25.5 cents per share, which is set to be paid on January 28, 2026, to shareholders of record as of January 6, 2026.
This announcement reflects Agilent's commitment to returning value to its shareholders and indicates a stable financial position. The decision to declare a dividend is a positive signal to investors, suggesting confidence in the company's ongoing profitability and cash flow.
Agilent Technologies is a leader in analytical and clinical laboratory technologies, generating $6.51 billion in revenue in fiscal year 2024. The company employs around 18,000 people globally, showcasing its significant presence in the market.
Future dividends will be subject to approval by Agilent's board of directors, which means that the amounts and timing may vary based on the company's performance and market conditions.
Wall Street analysts forecast A stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for A is 167.50 USD with a low forecast of 130.00 USD and a high forecast of 180.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
Wall Street analysts forecast A stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for A is 167.50 USD with a low forecast of 130.00 USD and a high forecast of 180.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
2 Hold
0 Sell
Strong Buy
Current: 133.870
Low
130.00
Averages
167.50
High
180.00
Current: 133.870
Low
130.00
Averages
167.50
High
180.00
HSBC
initiated
$180
2026-01-20
Reason
HSBC
Price Target
$180
AI Analysis
2026-01-20
initiated
Reason
HSBC initiated coverage of Agilent with a Buy rating and $180 price target. Agilent is a global leader in life sciences and diagnostics, and its is well positioned for sustained earnings growth, the analyst tells investors in a research note. The firm likes the shares into the ongoing liquid chromatography and mass spectrometry replacement cycle.
Evercore ISI
Evercore ISI
In Line -> Outperform
upgrade
$155 -> $160
2026-01-05
Reason
Evercore ISI
Evercore ISI
Price Target
$155 -> $160
2026-01-05
upgrade
In Line -> Outperform
Reason
As previously reported, Evercore ISI upgraded Agilent (A) to Outperform from In Line with a price target of $160, up from $155, upgraded Azenta (AZTA) to Outperform from In Line with a price target of $50, up from $34, upgraded iRhythm (IRTC) to Outperform from In Line with a price target of $210, up from $194, and upgraded Zimmer Biomet (ZBH) to Outperform from In Line with a price target of $120, up from $94, as part of a look-ahead note for the MedTech and Life Science Tools group. Conversely, the analyst downgraded Avantor (AVTR) to In Line from Outperform with a price target of $12, down from $14, downgraded Bausch + Lomb (BLCO) to In Line from Outperform with an unchanged price target of $18, downgraded Exact Sciences (EXAS) to In Line from Outperform with an unchanged price target of $105, downgraded Guardant Health (GH) to In Line from Outperform with a price target of $105, up from $90, downgraded Hologic (HOLX) to In Line from Outperform with a price target of $78, down from $79, and downgraded Bio-Techne (TECH) to In Line from Outperform with a price target of $62, down from $68. Recovering end markets and sector rotation have "set the stage for a 2026 Tools play," the analyst tells investors. In MedTech, the firm's survey work points to healthy procedure and CapEx trends into 2026 and early recovery signs in China support the group, but sector rotation and potential ACA and Medicare changes "have bears watching," the analyst added.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for A
Unlock Now
Evercore ISI
In Line -> Outperform
upgrade
$155 -> $160
2026-01-05
Reason
Evercore ISI
Price Target
$155 -> $160
2026-01-05
upgrade
In Line -> Outperform
Reason
Evercore ISI upgraded Agilent to Outperform from In Line with a price target of $160, up from $155.
Barclays
Equal Weight -> Overweight
upgrade
$165
2025-12-15
Reason
Barclays
Price Target
$165
2025-12-15
upgrade
Equal Weight -> Overweight
Reason
Barclays upgraded Agilent to Overweight from Equal Weight with an unchanged price target of $165. The firm adjusted ratings in the life sciences and diagnostics tools space as part of its 2026 outlook. The last of the estimate cuts, recovering end markets and tools being the "most under-owned space in healthcare" creates a "great setup" for outperformance of the tools group in 2026, the analyst tells investors in a research note.
About A
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
